Venetoclax 1257044-40-8

Description:

API Nomen Indicium Innovator Exitus patentibus Date (US)
Venetoclax 1257044-40-8 CLL Abbvie Jun.27,2031


Product Detail

Product Tags

Product SINGULA

维奈妥拉 Venetoclax 1257044-40-8 In-Domus
VCL-6A 98549-88-3 In-Domus
VCL-7A 1235865-75-4 In-Domus
VCLM2 1228780-72-0 In-Domus
VCLM2-2HCl 1628047-87-9 In-Domus
VCLM3 1228779-96-1 In-Domus

Gnomen eneric:venetoclax (ven ET oh klax)
Notam nomen: Venclexta, Venclexta Satus Pack

Venetoclax tractat chronica lymphocytica vel leukemia lymphocytica parva in adultis.Venetoclax sola adhibetur vel in compositione cum aliis medicamentis cancer ad has condiciones tractandas.

Venetoclax in compositione cum azacitidine, decitabine vel cytarabino adhibetur, ut leukemia myeloidalis acutae tractatur.Haec coniunctio usui est in adultis annis vel maior 75 vel qui non potest uti norma chemotherapy ob alias condiciones medicas.

Venetoclax interdum datur postquam aliae curationes defecerunt.

Venetoclax etiam adhiberi potest ad proposita in hoc medicamento duce non recensita.

Descriptio

Venetoclax (ABT-199; GDC-0199) est potentissima, selectiva et oretenus bioavailable Bcl-2 inhibitoris cum Ki minoris quam 0.01 nM.Venetoclax autophagiam inducit.

In vitro

Venetoclax (ABT-199) potenter cellas occidit FL5.12-BCL-2 (EC50=4 nM), Venetoclax (ABT-199) multum ostendit debiliorem actionem contra cellulas FL5.12-BCL-XL (EC50=261 nM).ABT-199 etiam ostendit selectivam in cellulosis pertentationibus mammalium duobus hybridis, ubi complexa BCL-2-BIM (EC50=3 nM) rumpit, sed multo minus efficax contra BCL-XL-BCL-XS (EC50=2.2μm) vel MCL-I-NOXA complexa.

Post unicam dosis oris 12.5 mg per kg pondus corporis in xenografts ex RS4 derivatis, cellulis 11 (ALL), Venetoclax (ABT-199) causat maximum incrementum inhibitionis tumoris (TGImax) 47% (P<0.001) et tumoris incrementi mora (TGD) de 26% (P<0.05) [1].

Sanatio xenografta stabilita (a mure xenografti exemplaris T-ALL lineae cellae LOUCY) tumores cum Venetoclax (ABT-199) 100 mg/kg per 4 dies resultat significantem deminutionem oneris leukemici.

Repono

Pulvis

-20°C

III annos

4°C

Annis II
In solvendo

-80°C

VI menses

-20°C

I mensis

Chemical structure

Venetoclax 1257044-40-8

CERTIFICATE

2018 GMP-2
原料药GMP证书201811(captopril ,thalidomide etc)
GMP-of-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

QUALITY MANAGEMENT

Quality management1

Rogatio18Qualitas Constantia Aestimatio inceptis quae probaverunt4, et6incepta approbantes.

Quality management2

Provectus qualitas internationalis administrandi ratio solidum fundamentum venditio posuit.

Quality management3

Qualitas vigilantia percurrit totum vitae cyclum producti, ut qualitatem et therapeuticum effectum curet.

Quality management4

Negotiis professionalibus regularibus turmas sustinet qualitatem postulatorum in applicatione et adnotatione.

PROLATIO MAGISTERIUM

cpf5
cpf6

Korea Countec Bottled Packaging linea

cpf7
cpf8

Taiwan CVC Bottled Packaging Line

cpf9
cpf10

Italia CAM Board Packaging Line

cpf11

German Fette Compacting Machine

cpf12

Iaponia Viswill Traba Detector

cpf14-1

DCS Control Room

SOCIUS

Cooperatio internationalis
International cooperation
Cooperatio domestica
Domestic cooperation

  • Previous:
  • Deinde:

  • Epistulam tuam hic scribe et mitte nobis